Artal Group S.A. Bellus Health Inc. Transaction History

Artal Group S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$8.22 - $10.76 $18.9 Million - $24.7 Million	-2,300,000 Reduced 38.33%	3,700,000 $30.4 Million
Q3 2022 Nov 14, 2022	SELL	$8.95 - $12.0 $8.95 Million - $12 Million	-1,000,000 Reduced 14.29%	6,000,000 $63.4 Million
Q2 2022 Aug 11, 2022	SELL	$6.46 - $10.02 $9.69 Million - $15 Million	-1,500,000 Reduced 17.65%	7,000,000 $64.7 Million
Q4 2021 Feb 11, 2022	BUY	$5.26 - $8.3 $17.1 Million - $27 Million	3,250,000 Added 61.9%	8,500,000 $68.4 Million
Q3 2021 Nov 12, 2021	BUY	$2.7 - $6.64 $1.35 Million - $3.32 Million	500,000 Added 10.53%	5,250,000 $32.2 Million
Q4 2020 Feb 11, 2021	BUY	$2.27 - $3.3 $9.7 Million - $14.1 Million	4,275,000 Added 900.0%	4,750,000 $14.5 Million
Q3 2020 Nov 13, 2020	BUY	$2.14 - $12.02 $708,847 - $3.98 Million	331,237 Added 230.4%	475,000 $1.08 Million
Q2 2020 Aug 14, 2020	BUY	$8.88 - $11.15 $1.28 Million - $1.6 Million	143,763 New	143,763 $1.48 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.